Kornimate/medical-research-clean huggingface dataset:
a randomized trial to evaluate efficacy and safety of intracavernosal injection of platelet-rich plasma versus phosphodiesterase type-5 inhibitors for treatment of erectile dysfunction.

Conditions: Erectile Dysfunction Following Radiation Therapy; Phosphodiesterase Inhibitor Adverse Reaction; Platelet- Rich Plasma (PRP)

Summary: the aim of this study is to evaluate the efficacy and safety of intracavernosal injection of prp in patients with moderate to severe ed.


Eligibility criteria:
inclusion criteria: * 1) signed an ethics committee-reviewed and approved informed consent form. 2) subjects must meet all inclusion criteria to be eligible for study enrollment. 3) men between 30 and 75 years old, 4) sexually active in a stable, heterosexual relationship of at least six months duration. 5) ed for at least 6 months with an iief-ef between 5 and 16 points, inclusive. 6) ed of vascular origin. 7) subjects agree to attempt vaginal intercourse at least 4 times every month after the end of the treatment and agree to document the outcome using the sexual encounter profile (sep) and the erection hardness score (ehs). 8) commitment not to use other treatment for ed during the study (herbal, topical, intraurethral, intracavernosal, etc.). 9) willingness and ability to comply with study procedures, other measurements instruments and visit schedules and able to follow oral and written instructions. exclusion criteria: * 1) refuse to complete study requirements. 2) psychogenic ed as determined by study investigator. 3) ed of neurogenic origin (radical cystectomy, radical prostatectomy, pelvic surgery, spinal cord injury, multiple sclerosis, dm is not included unless documented diabetic neuropathy). 4) previous penile surgery of any kind (except circumcision, frenuloplasty and condyloma removal), such as penile prosthesis, penile lengthening, penile cancer surgery, penile plication, grafting. 5) previous history of penile fracture, peyronie's disease or priapism. 6) previous radiation to pelvis. 7) history of symptomatic hypogonadism (testosterone level \<346ng/dl) not treated. 8) major hematologic, renal, or hepatic abnormalities. 9) severe decompensated cardiac, cns or vascular insufficiency. 10) poorly controlled hypertension or dm (hba1c \>12%). 11) neoplasm of any origin in active treatment or active progression or recovering from cancer within 12 months prior to enrollment. 12) history of alcohol abuse or drug. 13) treatment with oral anticoagulants, antiandrogens or nitrates. 14) thrombopenia less than 100 x 103 / l. 15) hemoglobin \<10g/dl. 16) poor venous access or any other circumstance that preclude an apheresis procedure. 17) sexually inactive in recent months. 18) participation in another study that may interfere with the results or conclusions of this study.

Keywords: erectile dysfunction , phosphodiesterase inhibitor adverse reaction, platelet- rich plasma
low-dose iron supplementation and markers of iron status among non-anemic, iron-deficient women

Conditions: Non-anemic Iron Deficiency

Summary: healthy premenopausal women that are iron-deficient without anemia will receive a low-dose iron dietary supplement. the investigators seek to determine if the low-dose iron dietary supplement will restore iron levels to normal range with fewer side effects than typically experienced at higher doses of iron supplementation.

the primary purpose of this clinical trial is to evaluate the impact of a low-dose iron dietary supplement on markers of iron status among a sample of premenopausal women that are iron-deficient without anemia. this study will also assess the incidence of mild adverse events (constipation, nausea, etc.) that are relatively common with other over the counter iron dietary supplements and that the investigators hypothesize will be reduced with this lower-dose formulation.

Eligibility criteria:
inclusion criteria: 1. pre-menopausal 2. iron deficient without anemia (serum ferritin concentration \ 120 g/l) 3. agree to continue with current diet and any dietary supplements 4. able to understand and write english 5. voluntarily consent to the study and understand its nature and purpose including potential risks and side effects exclusion criteria: 1. daily supplementation of another iron supplement (other than multivitamin) currently or within past 2 weeks 2. pregnant or breastfeeding females 3. history of alcohol, drug, or medication abuse 4. known allergies to any substance in the study product 5. donated blood in the past month or plan to do so at any time during the 8-week trial 6. current diagnosis of inflammatory bowel disease (crohn's or ulcerative colitis) 7. taking medication that my interfere with the absorption of iron 8. current tobacco smoker

Keywords: non-anemic iron deficiency, iron supplementation
dual site-dual channel non-invasive brain stimulation for motor function in stroke patients

Conditions: Stroke

Summary: the aim of this study is to investigate the effect of dual site-dual channel non-invasive brain stimulation for recovery of motor function in post stroke patients. simultaneous dual site-dual channel stimulation was applied by using two sets of transcranial direct current stimulation devices. all subjects will go through three conditions of transcranial direct current stimulation with for 30 minutes. three conditions are 1) dual stimulation 1: i) anodal stimulation on ipsilesional primary motor cortex and cathodal stimulation on contralesional primary motor cortex, ii) anodal stimulation on ipsilesional premotor cortex and cathodal stimulation on contralesional supraorbital area. 2) dual stimulation 2: i) anodal stimulation on ipsilesional primary motor cortex and cathodal stimulation on contralesional primary motor cortex, ii) anodal stimulation on ipsilesional anterior intraparietal sulcus and cathodal stimulation on contralesional supraorbital area. 3) single stimulation: anodal stimulation on ipsilesional primary motor cortex and cathodal stimulation on contralesional primary motor cortex.


Eligibility criteria:
inclusion criteria: * unilateral hemiplegic stroke patient * fugl meyer assessment score between 9 to 84 exclusion criteria: * difficult to understand experimental tasks because of extremely severe cognitive impairment * history of psychiatric disease

Keywords: transcranial direct current stimulation dual stimulation
the use of point-of-care ultrasound in the diagnosis of acute infectious mononucleosis in the emergency department

Conditions: Infectious Mononucleosis; Splenomegaly

Summary: the purpose of this study is to determine if splenomegaly on point-of-care ultrasound (pocus) is an accurate and user-friendly surrogate to the heterophile antibody test and epstein-barr virus (ebv) serologies to diagnose acute mononucleosis infection in patients presenting with sore throat to the emergency department (ed).

the investigators seek to determine whether the presence of splenomegaly on pocus can accurately diagnose acute infectious mononucleosis in symptomatic ed patients, and determine the feasibility of performing point-of-care ultrasound for splenomegaly by emergency physicians in the emergency department setting.

Eligibility criteria:
inclusion criteria: * patients aged between 10 and 35 year-old presenting to the ed with suspected acute infectious mononucleosis exclusion criteria: * chronic infectious disorders (eg. tuberculosis, malaria, hiv, syphilis) * inflammatory disorders (eg. sarcoidosis, amyloidosis, systemic lupus erythematosus, felty syndrome) * proliferative disorders (eg. lymphoma, leukemia, essential thrombocytopenia, polycythemia vera) * congestive disorders (eg: cirrhosis, portal hypertension, right heart failure, congenital heart disease) * chronic haemolytic anemia (eg. sickle cell, thalassemia, hereditary spherocytosis) * storage diseases (eg. gaucher, niemann-pick) * splenectomy * inability to give informed consent

Keywords: point-of-care ultrasound
paracetamol versus placebo in conjunction with strong opioids for cancer pain

Conditions: Pain

Summary: national guidelines advocate the use of paracetamol in conjunction with strong opioids for cancer pain, despite a lack of evidence for its efficacy. work is needed to examine the analgesic benefit of paracetamol in this large patient group. the investigators aim to establish if paracetamol in combination with strong opioids provides superior analgesia for cancer related pain over strong opioids alone.


Eligibility criteria:
inclusion criteria: 1. age 16 years and over 2. under palliative care/oncology service review 3. diagnosis of incurable cancer 4. clinician-predicted life expectancy \>2 months 5. anticipated to be clinically stable for duration of study involvement 6. receiving daily regular strong opioids 7. able to take study drug/placebo in its current form 8. prescribed and taking paracetamol 1g four times a day 9. average pain \>3 and \<9 in past 24 hours 10. able to provide written informed consent 11. able to complete necessary assessments required as part of the trial 12. average nrs pain score stable (ie. maximum range of 1 point) for the three consecutive days prior to randomisation exclusion criteria: 1. pain which the clinician deems to be unstable 2. clinically significant renal or liver disease 3. weight less than 50kg 4. those whose pain is expected to change during the course of the study as a result of oncological or other treatments 5. co-enrolment in other drug trials 6. known to be pregnant or breast-feeding at the time of recruitment 7. previously enrolled in this study
more response on cardiac resynchronization therapy with multipoint pacing

Conditions: Heart Failure

Summary: the purpose of this clinical investigation is to assess the impact of the multi point pacing (mpp) feature at 12 months in the treatment of patients not responding to standard cardiac resynchronization therapy (crt) after 6 months.

this study is designed as a prospective, randomized, multi-center trial. data will be collected at enrollment, baseline, implant procedure, patient classification, 6 months and 12 months of follow-up. during the 6-month visit, the patient's response to crt will be evaluated according to lvesv reduction. patients with an lvesv reduction of at least 15% will be classified as responders. these patients will terminate their participation in the study and return to the center's standard practice. patients with an lvesv reduction less than 15% will be classified as non-responders and the mpp feature will be activated according to randomization result and they will be followed until the 12-month visit.

Eligibility criteria:
inclusion criteria: * meets the current esc guidelines or accf/aha/hrs class i or class iia indications for crt implant (including upgrades from single or dual chamber icds) * must be willing and able to comply with study requirements * must indicate their understanding of the study and willingness to participate by signing an appropriate informed consent form exclusion criteria: * already had a crt device implanted * myocardial infarction, unstable angina within 40 days prior the enrollment * recent cardiac revascularization (ptca, stent or cabg) in the 4 weeks prior to enrollment or planned for the 3 months following * cerebrovascular accident (cva) or transient ischemic attack (tia) in the 3 months prior the enrollment * primary valvular disease * atrial fibrillation: * persistent af at the time of enrollment * permanent af not treated with av node ablation within 2 weeks from the crt implant * history or incidence of paroxysmal or persistent af within 30 days prior the enrollment * unable to comply with the follow up schedule * less than 18 years of age * pregnant or are planning to become pregnant during the duration of the investigation * classification of status 1 for cardiac transplantation or consideration for transplantation over the next 12 months * undergone a cardiac transplantation * life expectancy \< 12 months * currently participating in any other clinical investigation

Keywords: crt, non responders, multipoint pacing (mpp)
peer support for severe mental disorders

Conditions: Psychosis; Major Depression; Bipolar Disorder; Borderline Personality Disorder

Summary: the purpose of this study is to determine wether peer support is effective for the treatment of people with severe mental illness.

a randomized controlled multi center trial is conducted, where patients receive usual care in the control group and usual care with additional peer support for 6 month in the intervention group. psychosocial outcome criteria are collected pre intervention, after 6 month intervention and at one year follow up. days till hospitalization and days spent in hospital are collected for one year before recruitment and one year after recruitment.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of schizophrenia, unipolar depression, bipolar disorder, personality disorder exclusion criteria: * primary clinical diagnosis of addiction

Keywords: severe mental illness
comparison of blood pressure measurement with an omron hem-907 device in a clinical setting and a research setting

Conditions: Hypertension

Summary: automated office blood pressure (aobp) devices are recommended for high blood pressure diagnosis. one of those devices is the omron hem-907 (omron healthcare). it is currently not known if blood pressure measurements performed with this device in a clinical setting are equivalent to those made in a research setting. therefore, this randomized-controlled trial was designed. it aims to compare the blood pressure measurements performed in a clinical and a research setting. seventy patients will be included and randomized to a clinical/research or research/clinical sequence.

hypertension is a common condition, with an estimated prevalence around 20 percent in canada. it is a major risk factor for cardiovascular disease. recently, hypertension canada has updated its guidelines and recommend we should consider a 120 mm hg systolic blood pressure target in high-risk patients aged 50 years or older. this recommendation derives mainly from the sprint trial. in this trial, blood pressure was measured with an automated oscillometric blood pressure (aobp) device, the omron hem-907 (omron healthcare). however, it is not known if measurements performed with this device in a clinical setting are equivalent to those made in a research setting. therefore, this randomized-controlled trial was designed. it aims to compare the blood pressure measurements of 70 patients in a clinical and a research setting. patients will be randomized to a clinical/research or a research/clinical sequence.

Eligibility criteria:
inclusion criteria: * at least 18 years old * hypertensive or presumed hypertensive * patients with a scheduled visit at the ircm hypertension clinic. exclusion criteria: * limitation preventing the measurement of blood pressure * introduction or withdrawal of any blood pressure-modifying medication starting 4 weeks before the first and until the last study visit. * recreative drug use (except cannabis) * alcohol use of more than 4 drinks during the day * new symptoms during the research visit, that warrants a medical evaluation * mean systolic blood pressure \>180 mm hg or mean diastolic blood pressure \>110 mm hg (using aobp)

Keywords: hypertension, blood pressure, systolic, diastolic, aobp, omron hem-907, research, clinical
a correlation study of internal jugular vein variability under deep inhalation and propofol-induced hypotension

Conditions: Hemodynamic

Summary: the correlation between internal jugular vein variability during deep inhalation and the decrease in blood pressure during propofol induction.

1. ultrasound records at least one quiet breathing cycle and one deep inhalation cycle to calculate ijvv 2. propofol was infused target-controlled at 4 μg/ml, and changes in arterial blood pressure within 3 minutes of propofol induction were observed. 3. aim to conduct a prospective observational study to evaluate the correlation between internal jugular vein variability during deep inhalation and the decrease in blood pressure during propofol induction.

Eligibility criteria:
inclusion criteria: * age over 60 years * american society of anesthesiology (asa) status ⅱ-ⅲ * surgery with radial artery puncture * propofol induction exclusion criteria: * bmi≥30kg/m2 * people with short necks; * previous hypotension (systolic blood pressure \<90mmhg or mean arterial pressure \<65mmhg) * previous poorly controlled hypertension * cardiac insufficiency , ef value\<50% * upper limb deep vein thrombosis * history of radiotherapy or neck surgery * inability to maintain a supine position for necessary measurements * mechanical ventilation status or inability to take deep breaths patients * gastrointestinal surgery * patients allergic to propofol.

Keywords: internal jugular vein propofol hypotension hemodynamic
efficacy of proton pump inhibitor in prevention of clopidogrel-related peptic ulcer

Conditions: Peptic Ulcer

Summary: proton pump inhibitors (ppi) can prevent the recurrence of peptic ulcer in clopidogrel users.

the aim of the prospective, randomized study is to investigate the efficacy of ppi in prevention of ulcer recurrence for clopidogrel users. we plan to enroll 300 clopidogrel users without baseline gastroduodenal ulcer at initial endoscopy. the patients will be randomly assigned to receive either (1) esomeprazole (20 mg qd) plus clopidogrel or (2) clopidogrel treatment alone for 6 months. the ulcer recurrence rate between the treatment groups will be compared.

Eligibility criteria:
inclusion criteria: * we plan to enroll 300 clopidogrel users without baseline gastroduodenal ulcer at initial endoscopy. the patients will be randomly assigned to receive either (1) esomeprazole (20 mg qd) plus clopidogrel or (2) clopidogrel treatment alone for 6 months. exclusion criteria: * 1.serious disease 2.refuse informed consent

Keywords: proton pump inhibitor peptic ulcer clopidogrel prevention
database of patients treated with respiratory support

Conditions: Chronic Respiratory Failure

Summary: an observatory of patients registered in 22 local homecare associations in france, for respiratory diseases, with annual data update. demographic and clinical data are registered rendering possible extraction of clinical and prognostic data.

patients on treatment for respiratory failure and for sleep apnoea are registered on entry into treatment with recording of clincal and demographic data. data available on age, sex, region, respiratoy function, blood gases, smoking status and some bilogical data

Eligibility criteria:
inclusion criteria: * requiring respiratory support

Keywords: respiratory failure oxygen sleep apnoea ventilation
physiological disturbances associated with neonatal intraventricular hemorrhage

Conditions: Intraventricular Hemorrhage; Autoregulation

Summary: annually, almost 5,000 extremely low birth weight (9 ounces to about 2 lbs) infants born in the us survive with severe bleeding in the brain (intraventricular hemorrhage); this devastating complication of prematurity is associated with many problems, including mental retardation, cerebral palsy, and learning disabilities, that result in profound individual and familial consequences. in addition, lifetime care costs for these severely affected infants born in a single year exceed $3 billion. the huge individual and societal costs underscore the need for developing care strategies that may limit severe bleeding in the brain of these tiny infants. the overall goal of our research is to evaluate disturbances of brain blood flow in these tiny infants in order to predict which of them are at highest risk and to develop better intensive care techniques that will limit severe brain injury. 1. since most of these infants require ventilators (respirators) to survive, we will investigate how 2 different methods of ventilation affect brain injury. we believe that a new method of ventilation, allowing normal carbon dioxide levels, will normalize brain blood flow and lead to less bleeding in the brain. 2. we will also examine how treatment for low blood pressure in these infants may be associated with brain injury. we believe that most very premature infants with low blood pressure actually do worse if they are treated. we think that by allowing the infants to normalize blood pressure on their own will allow them to stabilize blood flow to the brain leading to less intraventricular hemorrhage. 3. in 10 premature infants with severe brain bleeding, we have developed a simple technique to identify intraventricular hemorrhage before it happens. apparently, the heart rate of infants who eventually develop severe intraventricular hemorrhage is less variable than infants who do not develop this. we plan to test this method in a large group of infants, to be able to predict which infants are at highest risk of developing intraventricular hemorrhage and who could most benefit from interventions that would reduce disturbances of brain blood flow.


Eligibility criteria:
inclusion criteria: * ventilated elbw (401-1000 grams) infants * 23 to 30 weeks' gestation * umbilical arterial catheter placed during newborn resuscitation exclusion criteria: * presence of complex congenital anomalies or chromosomal abnormality * presence of central nervous system malformation * infants with hydrops fetalis * infants in extremis * infants with early (\<3 hour of age) intraventricular hemorrhage

Keywords: hypercapnia normocapnia chronic lung disease periventricular leukomalacia intraventricular hemorrhage hypotension cerebral autoregulation heart rate variability autonomic nervous system detrended fluctuation analysis
study of an investigational vaccine in healthy infants in taiwan (v441-001)(completed)

Conditions: Diphtheria; Tetanus; Pertussis; Hepatitis B; Poliomyelitis

Summary: the purpose of this study is to evaluate the safety, tolerability, and immune response of an investigational vaccine being evaluated to reduce the incidence of diphtheria, pertussis, tetanus, hepatitis b, poliomyelitis, and haemophilus influenza type b.

the duration of treatment is 65 weeks.

Eligibility criteria:
inclusion criteria: * healthy infant who received hepatitis b vaccine within 5 days of birth and whose mother is negative to hepatitis b surface antigen exclusion criteria: * problems with immune system * recent illness with fever
exercise in adolescents with type 1 diabetes

Conditions: Type 1 Diabetes

Summary: regular physical activity is an important part of diabetes management in adolescents with type 1 diabetes (t1d). increased physical activity has several beneficial effects such as improved lipid profile, insulin sensitivity and quality of life. in addition, a reduced hba1c is often seen in association to increased physical activity. however, the effect on glycemic control and the acute glycemic response seems to differs between different types of exercise. this issue is poorly studied in adolescents with t1d and the mechanism behind this is not fully understood. the primary aim of this study was to compare the acute effects on glycemia of resistance and two aerobic continuous and intermittent exercise bouts in adolescents with type 1 diabetes. secondarily, the investigators want to compare the different exercise according to hormonal changes and expression of mrna in muscle. at a baseline visit the participants was tested for maximal oxygen consumption (pvo2peak) and maximal strength (1-rm). the study participants then performed three exercise bouts and one control session (resting), each on 45 minutes, in a randomized order. measurement was performed during and after the exercise.


Eligibility criteria:
inclusion criteria: * male * type 1 diabetes * hba1c \< 65 mol/mol at inclusion * regularly performing physical activity * aged 16-18 years old exclusion criteria: * less than 0.5 u/kg in insulin requirements * duration of diabetes less than one year.

Keywords: type 1 diabetes exercise adolescents